HR-Positive/HER2-Negative Metastatic Breast Cancer: Future Oral SERD Selection and Personalized Treatment Decision-Making

Dr. Adam Brufsky and the panel conclude the program by exploring future treatment considerations in HR-positive/HER2-negative metastatic breast cancer, including the expanding number of available oral SERDs and the factors that may influence treatment selection. Dr. Virginia Kaklamani, Dr. Rebecca Shatsky, and Dr. Rita Nanda discuss the challenges of sequencing therapies after progression on endocrine-based treatments and antibody-drug conjugates, emphasizing the importance of individualized clinical decision-making. The faculty highlight how patient-specific factors, prior treatment exposure, safety profiles, and potential combination strategies may shape future use of oral SERDs in clinical practice. The discussion also addresses practical considerations such as regulatory approvals, payer requirements, guideline recommendations, and real-world access to therapy. Throughout the conversation, the panel emphasizes that treatment decisions extend beyond clinical trial data alone and require careful consideration of disease biology, patient preferences, quality of life, and long-term treatment goals. The program concludes with a forward-looking discussion on how emerging endocrine therapies may further refine personalized care for patients with HR-positive/HER2-negative metastatic breast cancer.